• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Amgen (NQ: AMGN )

    305.99 +2.71 (+0.89%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 18, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,166,228
    Open 302.75
    Bid (Size) 303.33 (3)
    Ask (Size) 306.44 (1)
    Prev. Close 303.28
    Today's Range 302.02 - 306.55
    52wk Range 218.44 - 329.72
    Shares Outstanding N/A
    Dividend Yield 2.78%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Check Out What Whales Are Doing With AMGN
    Via Benzinga
    7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
    With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities. 
    Via InvestorPlace

    Performance

    YTD
    +2.89%
    +2.89%
    1 Month
    -2.72%
    -2.72%
    3 Month
    +12.61%
    +12.61%
    6 Month
    +9.89%
    +9.89%
    1 Year
    +33.86%
    +33.86%

    More News

    Read More
    Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines
    Via MarketBeat
    Exposures COVID-19
    Expert Ratings For Amgen
    Via Benzinga
    Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
    Via Investor's Business Daily
    Decoding Amgen's Options Activity: What's the Big Picture?
    Via Benzinga
    Market Whales and Their Recent Bets on AMGN Options
    Via Benzinga
    Here's How Much You Would Have Made Owning Amgen Stock In The Last 20 Years
    Via Benzinga
    3 Stocks to Buy as Ozempic Surges in Popularity
    Via InvestorPlace
    Why Big-Name Biotech Regeneron Pharma Just Joined The 1,000-Club
    Via Investor's Business Daily
    Skye Bioscience Pivots To Obesity After Glaucoma Flop; Shares Plummet
    Via Investor's Business Daily
    Is Geron Stock a Buy Following Its First New Drug Approval?
    Via The Motley Fool
    Amgen Seeks Expanded US Approval For Autoimmune Disease Drug Acquired Via $28B Horizon Deal
    Via Benzinga
    The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
    Via The Motley Fool
    Where Will Amgen Be in 3 Years?
    Via The Motley Fool
    If You Invested $1000 In This Stock 20 Years Ago, You Would Have $5,700 Today
    Via Benzinga
    Amgen Secures FDA Nod For Rare-Disease Treatment Biosimilar Based On AstraZeneca's Drug
    Via Benzinga
    Exposures Product Safety
    OZEM ETF: 7 Things to Know About the New Roundhill GLP-1 & Weight Loss ETF
    Via InvestorPlace
    Topics ETFs
    Amgen's Catching Up to Novo Nordisk and Eli Lilly. Should You Buy It?
    Via The Motley Fool
    What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday?
    Via Benzinga
    Exposures Product Safety
    Stocks to Buy: 7 Undeniable Dow Darlings to Pile Into Now
    Via InvestorPlace
    Topics Stocks
    Exposures US Equities
    EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic
    Via Benzinga
    Topics ETFs
    7 Reliable Blue-Chip Stocks That Cannot Miss
    Via InvestorPlace
    Amgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient Population
    Via Benzinga
    7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
    Via InvestorPlace
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.